Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Wyrick Susan D. 2. Issuer Name and Ticker or Trading Symbol Sana Biotechnology, Inc. [SANA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) See Remarks (Last) (First) (Middle) C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400 3. Date of Earliest Transaction (Month/Day/Year) 12/13/2024 (Street) SEATTLE, WA 98102 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 06/03/2025(1) M 10,000 A $ 0 170,395(2) D Common Stock 06/04/2025(1) F 2,567 D $2.32 167,828 D Common Stock 12/03/2025 M 10,000 A $ 0 180,828(3) D Common Stock 12/04/2025 F 2,565 D $4.44 178,263 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Restricted Stock Units

(4)

12/13/2024(1)

A

3,400

(5)

(5)

Common Stock

3,400

$ 0

3,400

D

Stock Option (Right to Buy)

$1.89

12/13/2024(1)

A

5,100

(6)

12/12/2034

Common Stock

5,100

$ 0

5,100

D

Restricted Stock Units

(4)

06/03/2025(1)

M

10,000

(7)

(7)

Common Stock

10,000

$ 0

10,000

D

Restricted Stock Units

(4)

12/03/2025

M

10,000

(7)

(7)

Common Stock

10,000

$ 0

0

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Wyrick Susan D. C/O SANA BIOTECHNOLOGY, INC. 188 EAST BLAINE STREET, SUITE 400 SEATTLE, WA 98102			See Remarks

Signatures

/s/ Aaron M. Grossman, Attorney-in-Fact for Susan D. Wyrick		12/05/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This transaction is being reported late due to an inadvertent administrative error and not any error of the reporting person.
(2)	Includes 3,000 shares acquired on May 15, 2025 pursuant to Sana Biotechnology, Inc.'s ("Sana") 2021 Employee Stock Purchase Plan (the "ESPP").
(3)	Includes 3,000 shares acquired on November 14, 2025 pursuant to the ESPP.
(4)	Each restricted stock unit represents a contingent right to receive one share of Sana common stock.
(5)	The award vests as to 100% of the restricted stock units on December 13, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.
(6)	The option vests as to 100% of the shares underlying the option on January 13, 2026, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.
(7)	The restricted stock units vested in two equal installments on each of June 3, 2025 and December 3, 2025.
Remarks: Acting Chief Financial Officer and Principal Accounting Officer; Exhibit List: Ex. 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.